Free Trial

Werewolf Therapeutics (HOWL) Stock Forecast & Price Target

Werewolf Therapeutics logo
$1.34 -0.01 (-0.74%)
Closing price 01/31/2025 04:00 PM Eastern
Extended Trading
$1.36 +0.02 (+1.87%)
As of 01/31/2025 07:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Werewolf Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
3

Based on 3 Wall Street analysts who have issued ratings for Werewolf Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 3 analysts, 3 have given a buy rating for HOWL.

Consensus Price Target

$9.33
596.52% Upside
According to the 3 analysts' twelve-month price targets for Werewolf Therapeutics, the average price target is $9.33. The highest price target for HOWL is $15.00, while the lowest price target for HOWL is $4.00. The average price target represents a forecasted upside of 596.52% from the current price of $1.34.
Get the Latest News and Ratings for HOWL and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Werewolf Therapeutics and its competitors.

Sign Up

HOWL Analyst Ratings Over Time

TypeCurrent Forecast
2/2/24 to 2/1/25
1 Month Ago
1/3/24 to 1/2/25
3 Months Ago
11/4/23 to 11/3/24
1 Year Ago
2/2/23 to 2/2/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$9.33$12.00$12.00$10.58
Forecasted Upside596.52% Upside669.23% Upside383.87% Upside95.47% Upside
Consensus Rating
Buy
Buy
Buy
Buy

HOWL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

HOWL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Werewolf Therapeutics Stock vs. The Competition

TypeWerewolf TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.82
2.53
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside596.52% Upside15,296.69% Upside12.26% Upside
News Sentiment Rating
Positive News

See Recent HOWL News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
1/14/2025JMP Securities
2 of 5 stars
Reni Benjamin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower TargetMarket Outperform ➝ Market Outperform$12.00 ➝ $4.00+196.29%
11/19/2024HC Wainwright
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$15.00 ➝ $15.00+777.19%
6/3/2024Wedbush
4 of 5 stars
 Reiterated RatingOutperform$9.00+125.56%
5/12/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$9.00 ➝ $10.00+250.88%
3/24/2023EF Hutton Acquisition Co. I
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy$8.30+282.49%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:17 AM ET.


HOWL Forecast - Frequently Asked Questions

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Werewolf Therapeutics is $9.33, with a high forecast of $15.00 and a low forecast of $4.00.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Werewolf Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" HOWL shares.

According to analysts, Werewolf Therapeutics's stock has a predicted upside of 596.52% based on their 12-month stock forecasts.

Werewolf Therapeutics has been rated by research analysts at HC Wainwright, and JMP Securities in the past 90 days.

Analysts like Werewolf Therapeutics more than other "medical" companies. The consensus rating for Werewolf Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how HOWL compares to other companies.


This page (NASDAQ:HOWL) was last updated on 2/1/2025 by MarketBeat.com Staff
From Our Partners